Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.44 |
| ▸ | PPARG | P37231 | 12/20 | 0.44 |
| ▸ | PPARA | Q07869 | 10/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220330 | 0.92 | PPARD (0.51) | PPARDPPARGPPARANAAACXCR3 | |
| SCHEMBL10220095 | 0.91 | PPARD (0.55) | PPARDPPARGPPARACXCR3MAPT | |
| SCHEMBL10220057 | 0.87 | PPARD (0.57) | PPARDPPARGPPARAMAPTPCSK9 | |
| SCHEMBL10219483 | 0.87 | PPARD (0.46) | PPARDPPARGPPARANAAACXCR3 | |
| SCHEMBL10220102 | 0.86 | PPARD (0.46) | PPARDPPARGPPARAMAPTALDH1A1 | |
| SCHEMBL10220098 | 0.84 | PPARD (0.48) | PPARDPPARGPPARAMAPTALDH1A1 | |
| SCHEMBL10220056 | 0.83 | PPARD (0.53) | PPARDPPARGPPARAMAPTTP53 | |
| SCHEMBL10220321 | 0.83 | PPARD (0.63) | PPARDPPARGPPARACXCR3 | |
| SCHEMBL10219985 | 0.82 | PPARD (0.47) | PPARDPPARGPPARANAAACXCR3 | |
| SCHEMBL10271404 | 0.81 | PPARG (0.40) | PPARDPPARGPPARANAAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.